Cargando…

Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries

The low prevalence of pancreatic cancer remains an obstacle to the development of effective screening tools in an asymptomatic population. However, development of effective serologic markers still offers the potential for improvement of diagnostic capabilities, especially for subpopulations of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rückert, Felix, Pilarsky, Christian, Grützmann, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835121/
https://www.ncbi.nlm.nih.gov/pubmed/24281109
http://dx.doi.org/10.3390/cancers2021107
_version_ 1782292104770224128
author Rückert, Felix
Pilarsky, Christian
Grützmann, Robert
author_facet Rückert, Felix
Pilarsky, Christian
Grützmann, Robert
author_sort Rückert, Felix
collection PubMed
description The low prevalence of pancreatic cancer remains an obstacle to the development of effective screening tools in an asymptomatic population. However, development of effective serologic markers still offers the potential for improvement of diagnostic capabilities, especially for subpopulations of patients with high risk for pancreatic cancer. The accurate identification of patients with pancreatic cancer and the exclusion of disease in those with benign disorders remain important goals. While clinical experience largely dismissed many candidate markers as useful markers of pancreatic cancer, CA19-9 continues to show promise. The present review highlights the development and the properties of different tumor markers in pancreatic cancer and their impact on the diagnostic and treatment of this aggressive disease.
format Online
Article
Text
id pubmed-3835121
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38351212013-11-21 Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries Rückert, Felix Pilarsky, Christian Grützmann, Robert Cancers (Basel) Review The low prevalence of pancreatic cancer remains an obstacle to the development of effective screening tools in an asymptomatic population. However, development of effective serologic markers still offers the potential for improvement of diagnostic capabilities, especially for subpopulations of patients with high risk for pancreatic cancer. The accurate identification of patients with pancreatic cancer and the exclusion of disease in those with benign disorders remain important goals. While clinical experience largely dismissed many candidate markers as useful markers of pancreatic cancer, CA19-9 continues to show promise. The present review highlights the development and the properties of different tumor markers in pancreatic cancer and their impact on the diagnostic and treatment of this aggressive disease. MDPI 2010-06-02 /pmc/articles/PMC3835121/ /pubmed/24281109 http://dx.doi.org/10.3390/cancers2021107 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Rückert, Felix
Pilarsky, Christian
Grützmann, Robert
Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
title Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
title_full Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
title_fullStr Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
title_full_unstemmed Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
title_short Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
title_sort serum tumor markers in pancreatic cancer—recent discoveries
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835121/
https://www.ncbi.nlm.nih.gov/pubmed/24281109
http://dx.doi.org/10.3390/cancers2021107
work_keys_str_mv AT ruckertfelix serumtumormarkersinpancreaticcancerrecentdiscoveries
AT pilarskychristian serumtumormarkersinpancreaticcancerrecentdiscoveries
AT grutzmannrobert serumtumormarkersinpancreaticcancerrecentdiscoveries